iREACH CDS Tool for Preventing Peanut Allergy
(iREACH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the iREACH CDS Tool, designed to help doctors follow guidelines that may prevent peanut allergies in young children. The goal is to determine if using this tool, along with education about the guidelines, can reduce peanut allergies by the time children reach 2.5 years old. The study compares doctors who use the tool and guidelines with those who do not. It suits caregivers whose infants have check-ups around 4 or 6 months old with participating pediatricians. As an unphased trial, this study allows caregivers to contribute to research that could influence future allergy prevention strategies.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the iREACH CDS Tool is safe for use in pediatric clinical settings?
Research has shown that the iREACH CDS Tool helps doctors follow guidelines to prevent peanut allergies in children. Studies have found that tools like iREACH can improve adherence to these guidelines.
No reports indicate that the iREACH CDS Tool causes harm, as it primarily guides doctors' decisions without involving medication or direct patient contact. Feedback from doctors using similar tools has been positive, with no serious issues reported. The tool is considered safe because it supports decision-making rather than directly treating patients.
In summary, the iREACH CDS Tool is safe and aids doctors in making better choices to prevent peanut allergies without any known risks to patients.12345Why are researchers excited about this trial?
Researchers are excited about the iREACH CDS Tool because it aims to enhance pediatricians' adherence to peanut allergy prevention guidelines through innovative integration with electronic health records. Unlike traditional methods that rely heavily on clinician memory and manual guideline consultation, this tool streamlines the decision-making process by automatically providing guideline-based recommendations. The hope is that this will lead to more consistent and effective implementation of prevention strategies, ultimately reducing the incidence of peanut allergies in children.
What evidence suggests that the iREACH CDS Tool is effective for preventing peanut allergy?
Research has shown that tools designed to assist doctors in decision-making can improve how pediatricians adhere to guidelines for preventing peanut allergies. In this trial, some pediatric clinicians will receive the iREACH CDS tool integrated into their practice. Studies have found that this tool helps doctors follow these guidelines more effectively. For instance, when integrated into electronic health records, these tools increase the likelihood of doctors discussing peanut introduction with parents, which is crucial for allergy prevention. One study demonstrated that these tools help doctors adhere to guidelines, potentially reducing the risk of children developing peanut allergies. These findings suggest that using the iREACH tool could enhance prevention outcomes for children at risk of peanut allergies.12346
Who Is on the Research Team?
Ruchi S Gupta
Principal Investigator
Ann & Robert H Lurie Children's Hospital of Chicago
Are You a Good Fit for This Trial?
This trial is for pediatric practices using an integrated EHR, clinicians providing infant care, and caregivers of infants seen for well-child visits at 4 or 6 months. Infants with conditions that risk PPA guideline implementation are excluded, as are temporary clinicians or non-English/Spanish speaking caregivers.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Pediatric clinicians receive the iREACH CDS tool and education on the PPA Guidelines to support adherence
Follow-up
Participants are monitored for adherence to guidelines and incidence of peanut allergy
What Are the Treatments Tested in This Trial?
Interventions
- iREACH CDS Tool
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ann & Robert H Lurie Children's Hospital of Chicago
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator